Cantel Medical — Investor Presentation (September 2010)
32 slides from Cantel Medical's investor presentation, Sep 15, 2010
Slide 1: Cantel Medical Corp. Dedicated to Infection Prevention & Control
Cantel Medical Corp. (NYSE: CMN) Dedicated to Infection Prevention & Control 09-15-2010 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements. All forward-looking statements involve risks and uncertainties, including, without limitation, the risks detailed in the Company’s
Slide 2: ~$275M NYSE Leader in Infection Prevention & Control
Cantel Medical Corp. ~$275M NYSE Leader in Infection Prevention & Control Expanding Global Awareness and Sensitivity to Infection Risk Large, growing market H1N1 (“Swine” Flu), MRSA, C.Diff, Staph Infections, etc. Leader in Infection Prevention & Control Niche Markets Medical device reprocessing, wa
Slide 3: Investing in significant upside growth opportunities
Cantel Medical Corp. ~$275M NYSE Leader in Infection Prevention & Control Investing in significant upside growth opportunities Leverage our capabilities in high-value liquid chemical germicides and filters Organic and licensed R&D pipeline Major push started in FY’10 in chemistry development within
Slide 4: $33B Global Market
4 Cantel Medical Corp. $33B Global Infection Prevention & Control Market Global IP&C Market (2006 US$M) U.S. Infection Prevention & Control Market (US$B) Forecast CAGR% 2006-2016 = 3.9% Infections in Medical Facilities are a Rapidly Growing Problem Annually, 2.3 Million People Acquire Infections in
Slide 5: Niche Orientation of Markets
5 Cantel Medical Corp. Niche Orientation of Infection Prevention & Control Markets 1 2 3 4 5 Brushes Disposable kits / trays Face shields Air filtration systems Aprons / bibs / arm protectors Dispensers Disposable medical products Masks Germicidal air cleaners Gloves Enzymatic cleaners Disposable su
Slide 6: Healthcare Reform Creates Greater Emphasis in IP&C
6 Cantel Medical Corp. Healthcare Reform Creates Greater Emphasis in IP&C Financial Penalties to Hospitals1 Preventable Readmissions – Estimated $25 billion cost to the system Beginning 2012, Medicare will stop paying hospitals for preventable readmissions tied to heart failure or pneumonia Beginnin
Slide 7: Three Synergistic Platforms
7 Cantel Medical Corp. Three Synergistic Platforms - PRODUCTS Infection Prevention & Control Focus Healthcare & Life Sciences Orientation Reprocessing Systems Renal Dialysis & Endoscopy Minntech; Medivators Purification & Filtration Water Treatment & Therapeutic Filters Mar Cor Purification; Minntec
Slide 8: Well-Balanced Portfolio of Products
8 Cantel Medical Corp. Well-Balanced Portfolio of PRODUCTS Last Twelve Months Ended April 30, 2010 (Q3’FY10)1 1 “All Other” includes Therapeutic Filtration Products and Specialty Packaging Products. 2 Before allocation of corporate expenses of ~$9.3M. 3 Earnings Before Interest, Taxes, Depreciation,
Slide 9: Strong Performance Over the Past Two Years
z Cantel Medical Corp. Strong PERFORMANCE Over the Past Two Years 1 Earnings before Interest, Taxes, Depreciation, Amortization, and Stock Compensation Expense. 2 Reflects abnormally large quarter due to Novel H1N1 (“Swine”) flu sales of facemasks. 3 Last Twelve Months Cash flow from Operations less
Slide 10: Significant Upside Growth Opportunities - Prospects
10 Cantel Medical Corp. Significant Upside Growth Opportunities - PROSPECTS Substantial Sales & Marketing investments in core FY’09-FY’10 Substantial increase in R&D spending in FY’11 R&D/Technology – High-Margin Liquid Chemical Germicides (LCG) BIOSAFE® antimicrobial coating technology – starting w
Slide 11: Significant Upside Growth Opportunities - New Markets, Alternative Channels
Cantel Medical Corp. Significant Upside Growth Opportunities - PROSPECTS New Markets – Alternative Channels Dedicated focus on corporate and government pandemic flu preparation One of only a few large U.S. manufacturers of FDA-cleared face masks Sponsored research study published demonstrating effec
Slide 12: Experienced People
12 Cantel Medical Corp. Experienced PEOPLE Andrew A. Krakauer President & CEO Former President of Ohmeda Medical (Division of Instrumentarium/GE) Over 20 years of healthcare experience Joined Cantel in 2004 as COO Craig A. Sheldon SVP, Chief Financial Officer & Treasurer Formerly with Ernst & Young
Slide 13: Segmentation Focus
13 Cantel Medical Corp. Segmentation Infection Prevention & Control Focus Healthcare & Life Sciences Orientation NYSE: CMN Renal / Dialysis Equipment, Sterilants, Consumables, Service Endoscope Reprocessing Equipment, Disinfectants, Consumables, Service Dental Disposables Water Purification Equipmen
Slide 14: Historical Income Statement Highlights
14 Cantel Medical Corp. Historical Income Statement Highlights 1 Reflects continuing operations and excludes any historical impact of Carsen Endoscopy & Surgical business. 2 Earnings before Interest, Taxes, Depreciation, Amortization, and Stock Compensation Expense. 3 Equivalent to “Income from Cont
Slide 15: Historical Balance Sheet Highlights
15 Cantel Medical Corp. Historical Balance Sheet Highlights 1 Earnings before Interest, Taxes, Depreciation, Amortization, and Stock Compensation Expense. 2 Reclassified long-term debt as current liability due to expiration date of revolver. Continuing Operations: Fiscal Year Ended July 31 US Dollar
Slide 16: Strategic Evolution
Cantel Medical Corp. Strategic Evolution 16 FY’04 – FY’08: Acquire and Define Infection Prevention & Control (ICP) Portfolio FY’09 – FY’10: Substantial Operational and P&L Improvement, while Investing in Sales & Marketing FY’11: Leverage Sales & Marketing and Drive R&D Investments. Close 1-2 Key Acq
Slide 17: Strategic Objectives Remain Focused
17 Cantel Medical Corp. Strategic Objectives Remain Focused within Infection Prevention & Control Build a profitable $500 Million Specialty Business Invest in higher technology, higher margin and higher growth organic programs with near-to-mid-term payoff Orientation around Liquid Chemical Germicide
Slide 18: Summary
Cantel Medical Corp. Summary Global, Growing $33B Market in Infection Prevention & Control Fragmented nature creates opportunities for further expansion ~$275M NYSE Specialty Infection Prevention & Control Leader 75% recurring revenue Selected for inclusion in the S&P SmallCap 600 Index Forbes 200 B
Slide 19: ( ) Dedicated to CROSSTEX
Cantel Medical Corp. (NYSE: CMN) Dedicated to Infection Prevention & Control CROSSTEX
Slide 20: Appendix Operating Segment Detail
Appendix Operating Segment Detail
Slide 21: Three Strategic Platforms
21 Cantel Medical Corp. Three Strategic Platforms Reprocessing Systems Renal Dialysis & Endoscopy Minntech Purification & Filtration Water Treatment Mar Cor Purification; Minntech Disposable Products Dental & Specialty Packaging Crosstex; Saf-T-Pak Infection Prevention & Control Focus Healthcare & L
Slide 22: Mar Cor Purification Process Water Value Comparison
22 Mar Cor Purification Process Water Value Comparison: Where We Participate Difficulty of water purification process Value Biologically Pure Water, Regulatory Impact Desalination Steam Generation Municipal drinking water Residential Medical Pharmaceutical Cosmetic/Topical Beverage Industrial Boiler
Slide 23: Mar Cor Purification Suite of Offerings
Mar Cor Purification Suite of Offerings Equipment Services Consumables (filters & disinfectants) 60% 20% 20% 23
Slide 24: Three Strategic Platforms
25 Cantel Medical Corp. Three Strategic Platforms Reprocessing Systems Renal Dialysis & Endoscopy Minntech Filtration & Purification Water Treatment Mar Cor Purification; Minntech Disposable Products Dental & Specialty Packaging Crosstex; Saf-T-Pak Infection Prevention & Control Focus Healthcare & L
Slide 25: Crosstex International Disposable Products - U.S. Dental Market
26 Crosstex International Disposable Products – U.S. Dental Market Dental Consumables Market (Retail)1 Approximately 70% of North American Dental Expenditures U.S. $4.4 Billion, growing historically at 6-7%/year, now (2%)-0% Comparison: Physician Medical Supply Market = $19 Billion2 Global ~ $10.5 B
Slide 26: Crosstex International U.S. Dental Market Structure
27 Crosstex International U.S. Dental Market Structure DENTISTS (156,000 Dentists / 120,000 Practices) (160,000 Hygienists / 200,000 Dental Assistants): 95+% Female DISTRIBUTORS Henry Schein (~40% share / 1,000 field reps / 90,000 sku’s (all prod.)) Patterson (~30% share / 1,550 field reps / 90,000
Slide 27: Crosstex International Disposable Products Portfolio
28 Crosstex International Disposable Products Portfolio 100 % >65% Manufactured In-House 0% Towels Tray Covers Masks / Shields Sterilization Accessories Headrest / Barrier Covers Cups Gloves Needles / Sharps Chemicals / Liquids Convenience Products Cotton Products Ejectors / Evacuators Prophy Angles
Slide 28: Three Strategic Platforms
29 Cantel Medical Corp. Three Strategic Platforms Reprocessing Systems Renal Dialysis & Endoscopy Minntech Filtration & Purification Water Treatment Mar Cor Purification; Minntech Disposable Products Dental & Specialty Packaging Crosstex; Saf-T-Pak Infection Prevention & Control Focus Healthcare & L
Slide 29: Medivators Flexible Endoscopy - Market Description
30 Medivators Flexible Endoscopy – Market Description Colorectal Cancer – 2nd Leading Cause of Death from Cancer – Early Screening U.S. G.I. market ~ $150 Million1 Worldwide G.I. Market ~ $300 Million 8% CAGR forecast for next 10 years2 Worldwide markets expanding at greater rate “Manual” Reprocessi
Slide 30: Medivators Flexible Endoscope Reprocessing - Full Product Range
31 Medivators Flexible Endoscope Reprocessing – Full Product Range EQUIPMENT Automatic Endoscope Reprocessors Leak Testers Scope Buddy CONSUMABLES/ ACCESSORIES Hook-up kits Scope cabinets Water Filtration Vapor management Carts SERVICE Field Service Install T&M Contracts Depot Service and Service Pa
Slide 31: Minntech Renal Dialysis - Market Description
32 Minntech Renal Renal Dialysis - Market Description Kidney Failure (End Stage Renal Disease) ~ 400,000 Patients in U.S.1 ~ 1,060,000 Patients Globally2 ~13% of American adults (26 million) have chronic kidney disease3 Kidney disease/failure is > 25% of Medicare’s annual expenditures3 Treatment Pro
Slide 32: Minntech Renal Dialysis - Products
33 Minntech Renal Renal Dialysis - Products Renatron Automated Reprocessing System for Rinsing, Cleansing, Sterilizing and Testing Dialyzers for Multiple Use (Capital Equipment) Renalin Peracetic Acid-Based Sterilant Utilized with Renatron Equipment (Consumables) Dialysate Concentrates used During H
Cantel Medical — Investor Presentation (September 2010) on 6ix